Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas
2001
Pharmacogenetics of Anticancer Drugs in Non-Hodgkin Lymphomas
publication
Author Information
Author(s): Loni L, Tacca M Del, Danesi R
Primary Institution: Interdepartmental Centre of Clinical Pharmacology and Experimental Therapeutics, University of Pisa, Italy
Hypothesis
The study aims to outline major genetic abnormalities in non-Hodgkin lymphomas that can be used to streamline anticancer drug selection.
Conclusion
Understanding genetic alterations in tumors can help tailor anticancer treatments to individual patients.
Supporting Evidence
- Advances in molecular pathology allow for profiling tumor cells for genetic background.
- Tailored anticancer treatments can be developed based on genetic alterations in tumors.
Takeaway
Doctors can use a patient's genetic information to choose the best cancer medicine for them.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website